人尾加压素Ⅱ的心血管效应及应用

Cardiovascular effect of human urotensin Ⅱ and its application

目的探讨血管活性物质尾加压素Ⅱ(UⅡ)在冠心病患者体内的作用。方法 40例冠心病患者作为冠心病组(稳定型心绞痛10例,不稳定型心绞痛21例,急性心肌梗死9例),20例健康体检者作为健康对照组,采用放射免疫法测定两组的血浆UⅡ水平。结果健康对照组的静脉血浆UⅡ的含量为(3.71±1.32)pg/ml,冠心病组患者的血浆UⅡ含量为(1.37±1.03)pg/ml,两组比较差异有统计学意义(P<0.05)。冠心病组内稳定型心绞痛、不稳定型心绞痛及急性心肌梗死患者的静脉血UⅡ水平分别为(2.62±1.21)、(1.38±0.82)、(1.05±0.48)pg/ml,三组比较差异有统计学意义(P<0.05)。结论 UⅡ可能参与冠心病发病,其在冠心病的发生、发展、预后的研究还只处于初步探讨阶段,有待临床进一步研究。

Objective To explore effect of vasoactive substance urotensin Ⅱ in coronary heart disease patients. Methods There were 40 coronary heart disease patients as coronary heart disease group（10 cases of stable angina pectoris, 21 cases of unstable angina pectoris and 9 cases of acute myocardial infarction）, and 20 health examination people as control group. Serum urotensin Ⅱ level of two groups were detected by radioimmunoassay. Results The control group had content of vein serum U Ⅱ as（3.71±1.32） pg/ml, and coronary heart disease group had content of vein serum U Ⅱ as（1.37±1.03） pg/ml, and their difference had statistical significance（P〈0.05）. The coronary heart disease group had content of vein serum U Ⅱ in stable angina pectoris, unstable angina pectoris and acute myocardial infarction respectively as（2.62±1.21）,（1.38±0.82）, and（1.05±0.48） pg/ml, difference had statistically significant in three groups（P〈0.05）. Conclusion U Ⅱ may participate in onset of coronary heart disease and its effect on occurrence, development and prognosis of coronary heart disease is still in preliminary exploration stage and still need further clinical research.